Summary
The product Semaglutide 5 mg/vial (SM5), with an ironlion-lab manufacturer, underwent independent testing to verify its authenticity and potency. The sample, with an unknown batch number, was submitted by ironlion-lab and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Semaglutide, with a concentration of 5.88 mg, which is 17.6% above the labeled claim of 5 mg per vial. The product’s purity was determined to be 99.855%.
The testing process began on 29 May 2024, with the sample received on 20 June 2024, and analysis completed on 24 June 2024. While the results confirm high purity, the higher-than-expected concentration raises concerns regarding dosing accuracy. Scrutiny of manufacturer-submitted samples remains essential to ensure reliability. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Iron Lion Pharma
- Product Name: Semaglutide 5 mg/vial (SM5)
- Active Ingredient: Semaglutide
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Viral Powder
Sample Acquisition and Testing
- Task Number: #44206
- Testing Ordered: 29 May 2024
- Sample Received: 20 June 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Iron Lion Pharma (Manufacturer)
- Analysis Paid For By: Iron Lion Pharma (Manufacturer)
Testing Results
- Specification: 5 mg (as stated on the label)
- Measured Concentration: 5.88 mg
- Accuracy: 117.6% (17.6% above the label claim)
- Purity: 99.855%
Verification Details
Verification URL: https://janoshik.com/tests/44206_2HBZ4CLSA1XU
Evaluation of Manufacturer-Submitted Testing
This analysis highlights that Semaglutide 5 mg/vial (SM5) contains Semaglutide at a higher concentration than labeled (5.88 mg instead of 5 mg per vial). While the purity is exceptionally high (99.855%), the excessive concentration raises concerns about manufacturing consistency and dosing accuracy. Since the test was submitted and funded by ironlion-lab, careful evaluation is necessary to assess product consistency across different batches. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple samples.
Conclusion
The analysis confirms that Semaglutide 5 mg/vial (SM5) contains 5.88 mg of Semaglutide per vial, which is 17.6% above the labeled claim. While this batch exhibits high purity (99.855%), the discrepancy in concentration underscores the importance of further testing to ensure accurate dosing across production batches. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical and peptide products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
